Atai Life Sciences (NASDAQ: ATAI)
Atai Life Sciences Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Atai Life Sciences Company Info
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.
News & Analysis
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
Atai's stock is hurting, but its pipeline is still packed with promising programs.
Why Shares of Atai Life Sciences Rose Friday
The company's co-founder and chairman increased his position and explained why.
Why Atai Life Sciences Stock Stormed Higher This Week
The biotech's strong financial position may be attracting bargain buyers right now.
Wall Street Thinks These 2 Penny Stocks Could Go Parabolic
Wall Street is bullish on these two beaten-down healthcare stocks.
Why Shares of atai Life Sciences Climbed 14.58% on Tuesday
The company specializes in developing psychedelics as therapies.
New Regulations for Psychedelics? Here's What Investors Need to Know
There are a couple of proposed regulations and policies in the pipeline.
These 4 Psychedelic Biotech Stocks Are Leading the Pack
Their clinical programs and research-enabling technologies both surpass the competition.
4 Green Flags for Psychedelic Drug Stocks
It's never been a better time to be a biotech developing psychedelic therapies.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.